To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …

The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

Cancer immunoediting is a hallmark of cancer that predicts that lymphocytes kill more
immunogenic cancer cells to cause less immunogenic clones to dominate a population …

Many primary-tumor subregions have low levels of molecular oxygen, termed hypoxia.
Hypoxic tumors are at elevated risk for local failure and distant metastasis, but the molecular …

Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients
surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few …

Abstract Treatment with immune checkpoint blockade (CPB) therapies often leads to
prolonged responses in patients with metastatic melanoma, but the common mechanisms of …

Cancer is a leading cause of death worldwide. Identifying the best treatment using
computational models to personalize drug response prediction holds great promise to …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …